Get the Daily Brief
Latest Biotech News
LB Pharmaceuticals IPO Signals Biotech Market Rebound
LB Pharmaceuticals closed a $285 million initial public offering, marking the largest biotech IPO in the U.S. for 2025 to date and breaking a seven-month drought in significant public biotech...
AI and Advanced Technologies Accelerate Multi-Omics Research and Laboratory Automation
Sapio Sciences and Ultima Genomics have partnered to integrate AI-powered lab informatics with high-throughput sequencing platforms, facilitating streamlined, scalable multi-omics workflows for...
Capsida Biotherapeutics Pauses Rare Disease Gene Therapy Trial After Patient Death
Capsida Biotherapeutics has halted its Phase I/II clinical trial of gene therapy CAP-002 targeting STXBP1 encephalopathy in pediatric patients following the death of the first enrolled child. The...
FDA Approvals and Regulatory Actions in Oncology and Therapeutics
The FDA granted approval for Johnson & Johnson’s Inlexzo, a drug-device combination delivering gemcitabine directly to the bladder for patients with BCG-unresponsive non-muscle invasive bladder...
AI Models Predict Therapeutic Targets and Advance Drug Discovery
Harvard Medical School researchers have developed PDGrapher, an artificial intelligence model that improves drug discovery by predicting combinatorial therapeutic targets capable of reversing...
Nanomedicine and Novel Drug Delivery Systems in Cancer Therapy
Recent advances in nanotechnology have produced innovative drug delivery platforms for targeted cancer therapy. Researchers developed poly-L-histidine-coated mesoporous silica nanoparticles for...
Breakthrough Research on Brain Function and Neurodegenerative Disease
Novel studies reveal crucial insights into brain aging, neurodegeneration, and potential therapeutic targets. Research from Calico Life Sciences et al. demonstrates that microglial aging is...
Merck pulls UK operations: £1.3 billion London lab scrapped
Merck has abruptly terminated its planned £1.3 billion research lab in London and will discontinue all discovery research operations in the UK. Citing lack of meaningful progress in life science...
Capsida gene therapy trial paused after patient death
Capsida Biotherapeutics has paused enrollment in its Phase I/II Synrgy clinical trial for STXBP1 encephalopathy, a rare pediatric neurodevelopmental disorder, following the death of the first...
LB Pharmaceuticals raises $285 million in Nasdaq debut
LB Pharmaceuticals successfully completed a $285 million IPO, marking the largest biopharma offering in the U.S. since February. The company plans to advance its oral schizophrenia drug LB-102, a...
FDA approves J&J’s intravesical delivery system for bladder cancer
Johnson & Johnson received FDA approval for Inlexzo (formerly TAR-200), a drug-device combination that delivers gemcitabine directly into the bladder for patients with BCG-unresponsive, non-muscle...
CRISPR therapy shows promise in treating rare vascular disease MSMDS
Researchers at Massachusetts General Hospital engineered a bespoke CRISPR-Cas9 base editor targeting the ACTA2 gene mutation underlying multisystemic smooth muscle dysfunction syndrome (MSMDS), a...
Innovative AI-driven drug discovery and lab automation partnerships
Sapio Sciences and Ultima Genomics announced a strategic partnership integrating Sapio’s AI-powered lab informatics platform with Ultima’s high-throughput, low-cost sequencing solutions to...
Breakthroughs in cancer immunotherapy and tumor microenvironment research
New immunotherapy approaches target previously resistant tumors by harnessing innate immune pathways. A potent ENPP1 inhibitor, STF-1623, developed by Stanford and Arc Institute researchers,...
Advances in protein-targeted drug discovery using AI and novel molecular platforms
Researchers have unveiled powerful new tools and molecules to accelerate drug discovery. Harvard Medical School scientists developed PDGrapher, an AI platform that predicts combinatorial targets...
UK life science industry faces competitive challenges and policy scrutiny
The UK’s life science sector is under increasing scrutiny as major companies like Merck exit research operations citing policy and market concerns. Trade groups including the ABPI warn that UK...
Merck Halts UK Operations: Exits London $1.3B Research Lab
Merck has announced the cancellation of its plans for a $1.3 billion research laboratory in London, citing dissatisfactory progress in UK life sciences investment and policies. This move...
Novo Nordisk Restructures Amid Market Pressures: 9,000 Jobs Cut
Novo Nordisk has announced a major restructuring initiative aiming to refocus on its core diabetes and obesity markets amid heightened competition and slowing growth in obesity drugs. The Danish...
LB Pharmaceuticals Raises $285M IPO for Schizophrenia and Bipolar Drug Trials
LB Pharmaceuticals successfully completed an upsized initial public offering raising $285 million, marking the largest biotech IPO of 2025 and breaking a seven-month dry spell in biotech equity...
Innovative Gene Editing and Therapy Advances in Rare Pediatric Diseases
Recent advances in gene editing have delivered promising preclinical results in treating rare genetic disorders such as multisystemic smooth muscle dysfunction syndrome (MSMDS). Researchers at...